PRLD Prelude Therapeutics Inc

Nasdaq preludetx.com


$ 1.56 $ 0.08 (5.41 %)    

Thursday, 13-Nov-2025 14:18:49 EST
QQQ $ 608.54 $ -9.14 (-1.48 %)
DIA $ 476.43 $ -4.93 (-1.02 %)
SPY $ 673.14 $ -7.34 (-1.08 %)
TLT $ 89.54 $ -0.26 (-0.29 %)
GLD $ 382.62 $ -4.66 (-1.2 %)
$ 1.47
$ 1.45
$ 1.55 x 700
$ 1.57 x 6
$ 1.44 - $ 1.62
$ 0.61 - $ 4.22
701,291
na
92.41M
$ 1.28
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-12-2025 09-30-2025 10-Q
2 08-14-2025 06-30-2025 10-Q
3 05-06-2025 03-31-2025 10-Q
4 03-10-2025 12-31-2024 10-K
5 11-06-2024 09-30-2024 10-Q
6 08-12-2024 06-30-2024 10-Q
7 05-07-2024 03-31-2024 10-Q
8 02-15-2024 12-31-2023 10-K
9 11-01-2023 09-30-2023 10-Q
10 08-03-2023 06-30-2023 10-Q
11 05-08-2023 03-31-2023 10-Q
12 03-15-2023 12-31-2022 10-K
13 11-14-2022 09-30-2022 10-Q
14 08-09-2022 06-30-2022 10-Q
15 05-10-2022 03-31-2022 10-Q
16 03-17-2022 12-31-2021 10-K
17 11-12-2021 09-30-2021 10-Q
18 08-12-2021 06-30-2021 10-Q
19 05-11-2021 03-31-2021 10-Q
20 03-16-2021 12-31-2020 10-K
21 11-10-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 prelude-therapeutics-q3-eps-026-beats-036-estimate-sales-6500m-up-from-3000m-yoy

Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of ...

Core News & Articles

PRLD: 70% | Prelude Therapeutics Signs Agreement For Incyte To Acquire JAK2V617F JH2 Inhibitor Program In Development For Patie...

Core News & Articles

Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology company, today announced an exclusive opti...

 prelude-therapeutics-granted-us-patent--us-12448389-b2-for-brm-targeting-compounds-and-associated-methods-of-use

https://ppubs.uspto.gov/api/pdf/downloadPdf/12448389?requestToken=eyJzdWIiOiJlZWQ3ZTE2MS1kZjI1LTQyNTktODVjNy02NmE4NGMzYWM1ZDciL...

 hc-wainwright--co-reiterates-buy-on-prelude-therapeutics-maintains-5-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Buy and maintains $5 price...

 jmp-securities-maintains-market-outperform-on-prelude-therapeutics-lowers-price-target-to-3

JMP Securities analyst Reni J. Benjamin maintains Prelude Therapeutics (NASDAQ:PRLD) with a Market Outperform and lowers the...

 prelude-therapeutics-q1-eps-042-beats-047-estimate

Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of ...

 hc-wainwright--co-reiterates-buy-on-prelude-therapeutics-maintains-5-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Buy and maintains $5 price...

 jmp-securities-reiterates-market-outperform-on-prelude-therapeutics-maintains-4-price-target

JMP Securities analyst Reni Benjamin reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Market Outperform and maintains $4...

 hc-wainwright--co-reiterates-buy-on-prelude-therapeutics-maintains-5-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Buy and maintains $5 price...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION